These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 28373470)

  • 1. Clinical Significance of Serum p53 Antibody in the Early Detection and Poor Prognosis of Gastric Cancer.
    Kunizaki M; Fukuda A; Wakata K; Tominaga T; Nonaka T; Miyazaki T; Matsumoto K; Sumida Y; Hidaka S; Yasutake T; Sawai T; Hamamoto R; Nanashima A; Nagayasu T
    Anticancer Res; 2017 Apr; 37(4):1979-1984. PubMed ID: 28373470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Colorectal Cancer.
    Kunizaki M; Sawai T; Takeshita H; Tominaga T; Hidaka S; To K; Miyazaki T; Hamamoto R; Nanashima A; Nagayasu T
    Anticancer Res; 2016 Aug; 36(8):4171-5. PubMed ID: 27466527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Value of Serum p53 Antibody in the Diagnosis and Prognosis of Esophageal Squamous Cell Carcinoma.
    Kunizaki M; Hamasaki K; Wakata K; Tobinaga S; Sumida Y; Hidaka S; Yasutake T; Miyazaki T; Matsumoto K; Yamasaki T; Sawai T; Hamamoto R; Nanashima A; Nagayasu T
    Anticancer Res; 2018 Mar; 38(3):1807-1813. PubMed ID: 29491120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of preoperative serum anti-p53 antibodies in gastric cancer.
    Nakajima K; Suzuki T; Shimada H; Hayashi H; Takeda A; Ochiai T
    Tumour Biol; 1999; 20(3):147-52. PubMed ID: 10213922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment.
    Tokunaga R; Sakamoto Y; Nakagawa S; Yoshida N; Baba H
    Surg Today; 2017 May; 47(5):636-642. PubMed ID: 28062920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of p53 autoantibodies in sera of gastric cancer patients and their prognostic relevance.
    Würl P; Weigmann F; Meye A; Fittkau M; Rose U; Berger D; Rath FW; Dralle H; Taubert H
    Scand J Gastroenterol; 1997 Nov; 32(11):1147-51. PubMed ID: 9399397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients.
    Ochiai H; Ohishi T; Osumi K; Tokuyama J; Urakami H; Seki S; Shimada A; Matsui A; Isobe Y; Murata Y; Endo T; Ishii Y; Hasegawa H; Matsumoto S; Kitagawa Y
    Surg Today; 2012 Jan; 42(2):164-8. PubMed ID: 22075664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of serum p53 antibody measurement in colorectal cancer: an examination of 1384 primary colorectal cancer patients.
    Yamaguchi T; Takii Y; Maruyama S
    Surg Today; 2014 Aug; 44(8):1529-35. PubMed ID: 23975589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients.
    Shimizu K; Ueda Y; Yamagishi H
    Gastric Cancer; 2005; 8(4):214-9. PubMed ID: 16328595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normalization of serum p53 antibody levels in patients after curative resection for colorectal cancer.
    Kawahara H; Watanabe K; Enomoto H; Toyama Y; Akiba T; Yanaga K
    Anticancer Res; 2013 May; 33(5):2221-5. PubMed ID: 23645779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection.
    Tang R; Yeh CY; Wang JY; Changchien CR; Chen JS; Hsieh LL
    Ann Surg Oncol; 2009 Sep; 16(9):2516-23. PubMed ID: 19565285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum anti-p53 antibodies in lung cancer: comparison with established tumor markers.
    Cioffi M; Vietri MT; Gazzerro P; Magnetta R; D'Auria A; Durante A; Nola E; Puca GA; Molinari AM
    Lung Cancer; 2001; 33(2-3):163-9. PubMed ID: 11551411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical assessment and prognostic evaluation of tumor markers in patients with gastric cancer.
    Jiexian J; Xiaoqin X; Lili D; Baoguo T; Ting S; Xianwen Z; Cunzhi H
    Int J Biol Markers; 2013 Jun; 28(2):192-200. PubMed ID: 23787496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum p53 antibody: useful for detecting gastric cancer but not for predicting prognosis after surgery.
    Oshima Y; Suzuki T; Yajima S; Nanami T; Shiratori F; Funahashi K; Shimada H
    Surg Today; 2020 Nov; 50(11):1402-1408. PubMed ID: 32458231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of Serum p53 Antibody as a Tumor Marker in Colorectal Cancer.
    Takahashi R; Sakamoto K; Sugimoto K; Motegi S; Tsukamoto R; Ichikawa R; Okazawa Y; Aoki J; Ishiyama S; Takahashi M; Kojima Y; Okuzawa A; Tomiki Y; Matsuoka J
    Dis Markers; 2019; 2019():2721876. PubMed ID: 31929839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unusually high levels of serum p53 antibody in recurrent gastric cancer.
    Kunizaki M; Hamasaki K; Wakata K; Hidaka S; Nagayasu T; Kinoshita Y
    Clin J Gastroenterol; 2017 Dec; 10(6):503-507. PubMed ID: 28952039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer.
    Feng F; Tian Y; Xu G; Liu Z; Liu S; Zheng G; Guo M; Lian X; Fan D; Zhang H
    BMC Cancer; 2017 Nov; 17(1):737. PubMed ID: 29121872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of Combined Detection of Serum CEA, CA72-4, CA19-9 and TSGF in the Diagnosis of Gastric Cancer.
    Yin LK; Sun XQ; Mou DZ
    Asian Pac J Cancer Prev; 2015; 16(9):3867-70. PubMed ID: 25987051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum p53 antibody as a potential tumor marker in extrahepatic cholangiocarcinoma.
    Okada R; Shimada H; Otsuka Y; Tsuchiya M; Ishii J; Katagiri T; Maeda T; Kubota Y; Nemoto T; Kaneko H
    Surg Today; 2017 Dec; 47(12):1492-1499. PubMed ID: 28508195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of serum and gastric juice levels of carcinoembryonic antigen, CA19.9 and CA72.4 in patients with gastric cancer.
    Tocchi A; Costa G; Lepre L; Liotta G; Mazzoni G; Cianetti A; Vannini P
    J Cancer Res Clin Oncol; 1998; 124(8):450-5. PubMed ID: 9750022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.